Navigation Links
Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
Date:9/30/2008

CAMBRIDGE, Mass., Sept. 30 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development of next-generation cellulosic ethanol and high-performance specialty enzymes, announced today that Janet Roemer, Executive Vice President and General Manager, Specialty Enzymes Business, will present at the upcoming William Blair & Company 2008 Small-Cap Growth Stock Conference. The presentation is scheduled to begin at 10:40 a.m. ET on Tuesday, October 7, 2008 and will take place at The Waldorf-Astoria Hotel in New York City.

More information about this event, including a live webcast, may be accessed by visiting the "Investors" section of Verenium's website at http://www.verenium.com. A webcast replay will be available approximately one hour after the live webcast ends and will be accessible for one month following the conference.

About Verenium

Verenium Corporation is a leader in the development and commercialization of cellulosic ethanol, an environmentally-friendly and renewable transportation fuel, as well as high-performance specialty enzymes for applications within the biofuels, industrial, and health and nutrition markets. The Company possesses integrated, end-to-end capabilities in pre-treatment, novel enzyme development, fermentation, engineering, and project development and is moving rapidly to commercialize its proprietary technology for the production of ethanol from a wide array of feedstocks, including sugarcane bagasse, dedicated energy crops, agricultural waste, and wood products. In addition to the vast potential for biofuels, a multitude of large-scale industrial opportunities exist for the Company for products derived from the production of low-cost, biomass-derived sugars. Verenium's Specialty Enzyme business harnesses the power of enzymes to create a broad range of specialty products to meet high-value commercial needs. Verenium's world class R&D organization is renowned for its capabilities in the rapid screening, identification, and expression of enzymes-proteins that act as the catalysts of biochemical reactions. For more information on Verenium, visit http://www.verenium.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include statements related to the Company's operations, capabilities, commercialization activities, target markets and cellulosic ethanol facilities, all of which are prospective. Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's new and uncertain technologies, risks associated with the costs, labor requirements and labor availability associated with Verenium's demonstration plant, risks associated with Verenium's ability to obtain additional capital to support its planned operations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, technological, regulatory, competitive and other risks related to development, production, and commercialization of cellulosic ethanol and other biofuels and the commercial prospects of those industries, Verenium's dependence on existing collaboration, manufacturing, and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercialized products, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, changes in the U.S. or global energy markets and laws and regulations applicable to them, and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's quarterly report on Form 10-Q for the three months ended June 30, 2008. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody

Sr. Corporate Communications Associate

617-674-5357

sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Appoints John F. Dee to Board of Directors
3. Verenium Reports Financial Results for the First Quarter 2008
4. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
5. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
6. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
7. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
8. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
9. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
10. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
11. Webcast Alert: Neogen Corporation to Announce 1st Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and NEW YORK , ... the near completion of their $7M Series B financing, ... top of the $3.5M led by Mesa Verde Venture ... 2016.  These resources will be directed towards further accelerating ... PCDx, a comprehensive genomic profiling test and expanding the ...
(Date:2/15/2017)... ... February 15, 2017 , ... Park Systems , a leader ... AFM operating software that drastically boosts productivity with single click reliable nanoscale images, is ... functions of setting up and taking the image once done manually by the operator ...
(Date:2/15/2017)... 2017  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), ... fourth quarter and full year ended December 31, ... for Vanda as we continued to demonstrate strong ... exclusivity for Fanapt," said Mihael H. Polymeropoulos, M.D., ... pipeline with important 2017 milestones underscores Vanda,s commitment ...
(Date:2/15/2017)... ... February 15, 2017 , ... Morris Midwest ( http://www.morrismidwest.com ... house and technology show, Morris Madness, March 14-15, 2017 in Roselle, Illinois. The ... Tsugami and Hardinge Group in addition to displays of tooling, accessories and other ...
Breaking Biology Technology:
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/26/2017)... 26, 2017  Crossmatch, a leading provider of security ... aimed at combatting fraud, waste and abuse in assistance ... the Action on Disaster Relief conference in ... UN agencies and foreign assistance organizations throughout ... abuse are a largely unacknowledged problem in the foreign ...
(Date:1/23/2017)... 23, 2017  The latest mobile market research from ... dropped dramatically. The quarterly average price of a biometric ... in Q4 2016.  There are now 120 sub-$150 models ... up from just 28 a year ago at an ... Maxine Most , Acuity Market Intelligence Principal, "Biometric ...
Breaking Biology News(10 mins):